Article

Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer

2022-03-23

Abstract excerpt

<h4>SUMMARY</h4> Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). While our understanding of the biology underlying immune checkpoint blockade in NSCLC is still incomplete, studies to date have established predictive roles for PD-L1 tumor expression and tumor mutational burden (TMB). To expand our understanding of the molecular features underlying res...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f82cccbe-78a3-5361-823d-ece8d38730be
DOI: 10.1101/2022.03.21.485199

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung CancerDOI 10.1101/2022.03.21.485199Read

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerSemantic proximity Read

Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.Semantic proximity Read

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancerSemantic proximity Read

UBE3A deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer.Semantic proximity Read

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.Semantic proximity Read

Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.Semantic proximity Read

Tumor microenvironment and drug resistance in lung adenocarcinoma: molecular mechanisms, prognostic implications, and therapeutic strategiesSemantic proximity Read

Genomic Insights Guiding Personalized First-Line Immunotherapy Response in Lung and Bladder TumorsSemantic proximity Read

Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.Semantic proximity Read

Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancerSemantic proximity Read

A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancerSemantic proximity Read

PSMB5-centered immunotherapy resistance signature predicts prognosis and drives CD8+ T cell exclusion in lung adenocarcinomaSemantic proximity Read